UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1331-5
Program Prior Authorization/Notification
Medications Enspryng™ (satralizumab-mwge)
P&T Approval Date 10/2020, 10/2021, 10/2022, 10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Enspryng (satralizumab-mwge) is an interleukin-6 (IL-6) receptor antagonist indicated for the
treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-
aquaporin-4 (AQP4) antibody positive.
2. Coverage Criteriaa:
A. Initial Authorization
1. Enspryng will be approved based on all of the following criteria:
a. Diagnosis of neuromyelitis optica spectrum disorder (NMOSD)
-AND-
b. Patient has a positive serologic test for anti-aquaporin-4 (AQP4) antibodies
-AND-
c. Patient is not receiving Enspryng in combination with any of the following:
(1) Disease modifying therapies for the treatment of multiple sclerosis [e.g., Gilenya
(fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.]
(2) Complement inhibitors [e.g., Soliris (eculizumab), Ultomiris (ravulizumab), etc.]
(3) Anti-IL6 therapy [e.g., Actemra (tocilizumab)]
(4) B-cell depletion therapy [e.g., rituximab, Uplizna (inebilizumb-cdon)]
Authorization will be issued for 12 months.
B. Reauthorization
1. Enspryng will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Enspryng therapy
-AND-
b. Patient is not receiving Enspryng in combination with any of the following:
© 2024 UnitedHealthcare Services, Inc.
1
(1) Disease modifying therapies for the treatment of multiple sclerosis [e.g., Gilenya
(fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.]
(2) Complement inhibitors [e.g., Soliris (eculizumab), Ultomiris (ravulizumab), etc.]
(3) Anti-IL6 therapy [e.g., Actemra (tocilizumab)]
(4) B-cell depletion therapy [e.g., rituximab, Uplizna (inebilizumb-cdon)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Medical Necessity, Supply limits may be in place.
4. References:
1. Enspryng [package insert]. South San Francisco, CA: Genentech, Inc.; March 2022.
Program Prior Authorization/Notification – Enspryng (satralizumab-mwge)
Change Control
10/2020 New program.
10/2021 Annual review with no changes to clinical criteria.
10/2022 Annual review with no changes to clinical criteria. Added state
mandate footnote. Updated reference.
10/2023 Annual review. No changes.
10/2024 Annual review. No changes to coverage criteria. Updated examples of
complement inhibitors.
© 2024 UnitedHealthcare Services, Inc.
2